Edition:
United States

Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

8.16USD
15 Dec 2017
Change (% chg)

$0.61 (+8.08%)
Prev Close
$7.55
Open
$7.55
Day's High
$8.20
Day's Low
$7.55
Volume
28,792
Avg. Vol
5,683
52-wk High
$21.31
52-wk Low
$3.41

Summary

Name Age Since Current Position

Joshua Silverman

46 2016 Chairman of the Board

Daniel Alkon

73 2016 President, Chief Scientific Officer

Susanne Wilke

53 2016 Chief Executive Officer, Director

William Singer

74 2013 Vice Chairman of the Board

Robert Weinstein

2013 Chief Financial Officer, Executive Vice President

Paula Trzepacz

2016 Executive Vice President and Chief Medical Officer

Bruce Bernstein

2016 Director

Kenneth Gorelick

2016 Director

Andrew Perlman

2017 Director

Shana Phares

2016 Director

James Gottlieb

2013 Independent Director

Biographies

Name Description

Joshua Silverman

Mr. Joshua N. Silverman is Chairman of the Board of the Company. He co-founder of Iroquois Capital Management, LLC.

Daniel Alkon

Dr. Daniel Alkon, M.D., serves as President, Chief Scientific Officer of the Company. Dr. Alkon has been the founding Scientific Director of BRNI since 1999. He received his undergraduate degree in chemistry in 1965 at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his 30 year career he became a Medical Director in the U.S. Public Health Service at the National Institute of Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. Dr. Alkon occupied the Toyota Chair in Neurodegenerative diseases at BRNI from June 2006 until September 23, 2016. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly Alzheimer’s disease. From October 2000 until September 23, 2016, he was also a Professor at BRNI and a Professor of Neurology at West Virginia University.

Susanne Wilke

Dr. Susanne Wilke, Ph.D., M.B.A., has been appointed as Chief Executive Officer, Director of Neurotrope, Inc. Dr. Wilke, has been a member of the Board of Directors since February 15, 2016. Dr. Wilke has years of experience in the biotechnology industry, with a focus on the pharmaceutical, diagnostic and therapeutic fields. Since August 2011, Dr. Wilke has served as President and Chief Executive Officer at CrossBridge International, LLC, an advisory firm she co-founded that specializes in integrating proprietary scientific developments with marketing and financial planning services. From January 2011 through August 2011, Dr. Wilke served as a consultant at The Monitor Group in New York. Her previous employment experience includes positions as Director of Worldwide New Product Assessment for General Medicine and Specialty Pharmaceuticals at Forest Laboratories, as Senior Associate and later Principal at NGN Capital, as Kauffman Fellow in Venture Capital at Schroder Ventures Life Sciences and as Project Leader for Metabolic Diseases at Hoffmann-La-Roche. Dr. Wilke holds a B.A. in Chemistry from Loyola University, a PhD in Organic Chemistry/Biochemistry and Drug Development from the University of Illinois and an M.B.A. from the Dartmouth Tuck School of Business.

William Singer

Mr. William S. Singer is Vice Chairman of the Board of Neurotrope, Inc., since August 23, 2013. Mr. Singer serves as President of Blanchette Rockefeller Neurosciences Institute (“BRNI”) and is also on its board of directors. He was a partner in the Chicago office of the law firm of Kirkland & Ellis LLP from 1980 until 2006 and has been of counsel to that firm since that time, concentrating his practice on corporate, real estate, and legislative matters. Since 2006, he also has been the sole proprietor of Singer Consulting LLC, which advises clients on federal legislation. He has been listed in Crain’s Who’s Who in Chicago Business in the 2000, 2001, 2002, 2003, and 2004 editions.

Robert Weinstein

Mr. Robert Weinstein is Chief Financial Officer, Executive Vice President of Neurotrope, Inc., (Formerly BlueFlash Communications, Inc.), effective Ooctober 7, 2013. Prior to joining Neurotrope, Mr. Weinstein was a financial and accounting consultant to several healthcare companies in the pharmaceutical, medical device and biotechnology industries. Prior to his consulting roles, Mr. Weinstein was the Chief Financial Officer of three publicly traded companies, consistently increasing shareholder value through an active role in investor relations while partnering with senior management to provide strategic guidance and leading all Securities and Exchange Commission filing compliance. Prior to his senior officer and consulting positions, Mr. Weinstein was a founding partner in a highly successful healthcare-oriented private equity fund and an investment banker focused on micro-cap company financings and mergers & acquisitions. He is a certified public accountant and earned his Masters of Business Administration at The University of Chicago Graduate School of Business.

Paula Trzepacz

Dr. Paula T. Trzepacz is Executive Vice President and Chief Medical Officer of the Company. Prior to joining Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she was most recently a Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years Dr. Trzepacz was the medical lead for registration and regulatory related issues for its Attention Deficit Hyperactivity Disorder indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.

Bruce Bernstein

Kenneth Gorelick

Dr. Kenneth J. Gorelick is Director of the Company. Dr. Gorelick is the Managing Director of Zymo Consulting Group LLC, that provides consulting services to the biopharmaceutical industry, specializing in clinical development and regulatory affairs. He currently serves as Chair of the Program Advisory Board for Asahi Kasei Pharma America and as Chief Medical Officer for PIN Pharma, among others. Dr. Gorelick received his MD from Cornell University, and post-doctoral training at St. Louis University and Stanford University where he was also a member of the clinical faculty. Previously he was Vice President of Global Clinical Research and Development at DuPont Merck Pharmaceutical Company.

Andrew Perlman

Shana Phares

James Gottlieb

Mr. James Gottlieb is an Independent Director of the Company Effective 12 January, 2013. He has extensive senior level experience in a broad range of positions in Washington, D.C., in the U.S. House and Senate, and in the private and non-profit sectors. During his time in Washington, Mr. Gottlieb directed significant congressional policy and oversight matters regarding the Food and Drug Administration (“FDA”) and health-related aspects of the Veterans Administration, the largest civilian health provider in the nation. Mr. Gottlieb is currently a partner with Capital Counsel LLC, where he leads the commerce team. His clients include a broad range of matters including healthcare, aviation, telecommunications, e-commerce, oversight and investigations and mergers & acquisitions. Prior to joining Capital Counsel LLC and based upon his in-depth experience in legislation, oversight and investigations (including with the FDA) and political roles on Capitol Hill, and foundation management, consulting and strategic advisory roles outside of government, Mr. Gottlieb formed Gottlieb Strategic Consulting, a government affairs firm. Mr. Gottlieb served as the chief of staff for Representative Ted Weiss (D-NY) and later the Subcommittee on Human Resources & Government Relations of the House Committee on Government Operations (now Committee on Oversight & Government Reform), where he directed a wide range of oversight investigation and legislation in health, education, and veterans’ matters. He served as a Board of Directors member of BRNI and serves as Treasurer of Friends of Jay Rockefeller. Mr. Gottlieb received a B.A. in Business Administration from Michigan State University, a Master of Education from New York University and a law degree from New York Law School.